|
NXP900 Clinical Trials
2 actively recruiting trials across 2 locations
Pipeline
Phase 1: 2
Top Sponsors
- Nuvectis Pharma, Inc.2
Indications
- Lung Cancer2
- Cancer2
- Non-small Cell Lung Adenocarcinoma1
- EGFR Mutated Non-small Cell Lung Cancer Patients1
- EGFR Mutation Positive Non-small Cell Lung Cancer1
Phoenix, Arizona1 trial
Phase 1
Boston, Massachusetts1 trial
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Massachusetts General Hospital
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.